CoChat
Sign Up
Cited by 166

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Secretion of Tau via an Unconventional Non-vesicular Mechanism

Merezhko, Maria, Brunello, Cecilia A., Yan, Xu, Vihinen, Helena, Jokitalo, Eija, Uronen, Riikka-Liisa, Huttunen, Henri J.·2018·Cell Reports
DOI 10.1016/j.celrep.2018.10.078
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.celrep.2018.10.078

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Accelerated tau secretion represents an early and specific manifestation of tau pathology in Alzheimer's disease distinct from other tauopathies, occurring via active unconventional secretion.

    “It is now understood that accelerated tau secretion represents an early and specific manifestation of tau pathology in AD that is distinct from other tauopathies (Zetterberg, 2017), which occurs via active unconventional secretion (Merezhko et al., 2018).”

    From The neuronal retromer can regulate both neuronal and microglial phenotypes of Alzheimer's disease (2022) · cites this paper as Merezhko et al., 2018

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 48

  1. Akbar, 2005, Docosahexaenoic acid: a positive modulator of Akt signaling in neuronal survival, Proc. Natl. Acad. Sci. USA, 102, 10858, 10.1073/pnas.0502903102 · DOI
  2. Akoury, 2013, Inhibition of tau filament formation by conformational modulation, J. Am. Chem. Soc., 135, 2853, 10.1021/ja312471h · DOI
  3. Brandt, 1995, Interaction of tau with the neural plasma membrane mediated by tau’s amino-terminal projection domain, J. Cell Biol., 131, 1327, 10.1083/jcb.131.5.1327 · DOI
  4. Brunello, 2016, Internalized Tau sensitizes cells to stress by promoting formation and stability of stress granules, Sci. Rep., 6, 30498, 10.1038/srep30498 · DOI
  5. Bulic, 2013, Progress and developments in tau aggregation inhibitors for Alzheimer disease, J. Med. Chem., 56, 4135, 10.1021/jm3017317 · DOI
  6. Cisek, 2014, Structure and mechanism of action of tau aggregation inhibitors, Curr. Alzheimer Res., 11, 918, 10.2174/1567205011666141107150331 · DOI
  7. Dujardin, 2014, Ectosomes: a new mechanism for non-exosomal secretion of tau protein, PLoS ONE, 9, e100760, 10.1371/journal.pone.0100760 · DOI
  8. Ehrnhoefer, 2008, EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers, Nat. Struct. Mol. Biol., 15, 558, 10.1038/nsmb.1437 · DOI
  9. Elbaum-Garfinkle, 2010, The role of the lipid bilayer in tau aggregation, Biophys. J., 98, 2722, 10.1016/j.bpj.2010.03.013 · DOI
  10. Ercan, 2017, A validated antibody panel for the characterization of tau post-translational modifications, Mol. Neurodegener., 12, 87, 10.1186/s13024-017-0229-1 · DOI
  11. Flach, 2012, Tau oligomers impair artificial membrane integrity and cellular viability, J. Biol. Chem., 287, 43223, 10.1074/jbc.M112.396176 · DOI · Paper page
  12. Freund Levi, 2014, Transfer of omega-3 fatty acids across the blood-brain barrier after dietary supplementation with a docosahexaenoic acid-rich omega-3 fatty acid preparation in patients with Alzheimer’s disease: the OmegAD study, J. Intern. Med., 275, 428, 10.1111/joim.12166 · DOI
  13. Georgieva, 2014, Tau binds to lipid membrane surfaces via short amphipathic helices located in its microtubule-binding repeats, Biophys. J., 107, 1441, 10.1016/j.bpj.2014.07.046 · DOI
  14. Goedert, 2017, Propagation of Tau Aggregates and Neurodegeneration, Annu. Rev. Neurosci., 40, 189, 10.1146/annurev-neuro-072116-031153 · DOI · Paper page
  15. Hasegawa, 1997, Alzheimer-like changes in microtubule-associated protein Tau induced by sulfated glycosaminoglycans. Inhibition of microtubule binding, stimulation of phosphorylation, and filament assembly depend on the degree of sulfation, J. Biol. Chem., 272, 33118, 10.1074/jbc.272.52.33118 · DOI
  16. Hoffmann, 1997, Oxidized and phosphorylated synthetic peptides corresponding to the second and third tubulin-binding repeats of the tau protein reveal structural features of paired helical filament assembly, J. Pept. Res., 50, 132, 10.1111/j.1399-3011.1997.tb01178.x · DOI
  17. Jones, 2012, Interaction of tau protein with model lipid membranes induces tau structural compaction and membrane disruption, Biochemistry, 51, 2539, 10.1021/bi201857v · DOI
  18. Katsinelos, 2018, Unconventional Secretion Mediates the Trans-cellular Spreading of Tau, Cell Rep., 23, 2039, 10.1016/j.celrep.2018.04.056 · DOI
  19. Kawarabayashi, 2004, Dimeric amyloid beta protein rapidly accumulates in lipid rafts followed by apolipoprotein E and phosphorylated tau accumulation in the Tg2576 mouse model of Alzheimer’s disease, J. Neurosci., 24, 3801, 10.1523/JNEUROSCI.5543-03.2004 · DOI · Paper page
  20. Kuja-Panula, 2003, AMIGO, a transmembrane protein implicated in axon tract development, defines a novel protein family with leucine-rich repeats, J. Cell Biol., 160, 963, 10.1083/jcb.200209074 · DOI
  21. Künze, 2012, Binding of the three-repeat domain of tau to phospholipid membranes induces an aggregated-like state of the protein, Biochim. Biophys. Acta, 1818, 2302, 10.1016/j.bbamem.2012.03.019 · DOI
  22. Lasagna-Reeves, 2012, Identification of oligomers at early stages of tau aggregation in Alzheimer’s disease, FASEB J., 26, 1946, 10.1096/fj.11-199851 · DOI · Paper page
  23. Lasagna-Reeves, 2014, The formation of tau pore-like structures is prevalent and cell specific: possible implications for the disease phenotypes, Acta Neuropathol. Commun., 2, 56, 10.1186/2051-5960-2-56 · DOI
  24. LoPresti, 1995, Functional implications for the microtubule-associated protein tau: localization in oligodendrocytes, Proc. Natl. Acad. Sci. USA, 92, 10369, 10.1073/pnas.92.22.10369 · DOI · Paper page
  25. Mahammad, 2015, Cholesterol depletion using methyl-β-cyclodextrin, Methods Mol. Biol., 1232, 91, 10.1007/978-1-4939-1752-5_8 · DOI
  26. McLean, 1974, Periodate-lysine-paraformaldehyde fixative. A new fixation for immunoelectron microscopy, J. Histochem. Cytochem, 22, 1077, 10.1177/22.12.1077 · DOI
  27. Mercken, 1992, Monoclonal antibodies with selective specificity for Alzheimer Tau are directed against phosphatase-sensitive epitopes, Acta Neuropathol., 84, 265, 10.1007/BF00227819 · DOI
  28. Niman, 1983, Generation of protein-reactive antibodies by short peptides is an event of high frequency: implications for the structural basis of immune recognition, Proc. Natl. Acad. Sci. USA, 80, 4949, 10.1073/pnas.80.16.4949 · DOI
  29. Patel, 2015, Ion Channel Formation by Tau Protein: Implications for Alzheimer’s Disease and Tauopathies, Biochemistry, 54, 7320, 10.1021/acs.biochem.5b00988 · DOI
  30. Patra, 2008, Molecular targets of (-)-epigallocatechin-3-gallate (EGCG): specificity and interaction with membrane lipid rafts, J. Physiol. Pharmacol., 59, 217
  31. Pickhardt, 2005, Anthraquinones inhibit tau aggregation and dissolve Alzheimer’s paired helical filaments in vitro and in cells, J. Biol. Chem., 280, 3628, 10.1074/jbc.M410984200 · DOI
  32. Pickhardt, 2007, Phenylthiazolyl-hydrazide and its derivatives are potent inhibitors of tau aggregation and toxicity in vitro and in cells, Biochemistry, 46, 10016, 10.1021/bi700878g · DOI
  33. Rabouille, 2017, Pathways of Unconventional Protein Secretion, Trends Cell Biol., 27, 230, 10.1016/j.tcb.2016.11.007 · DOI
  34. Remy, 2006, A highly sensitive protein-protein interaction assay based on Gaussia luciferase, Nat. Methods, 3, 977, 10.1038/nmeth979 · DOI
  35. Reynolds, 2001, Phospholipid fatty acids and neurotoxicity in human neuroblastoma SH-SY5Y cells, Neurosci. Lett., 309, 193, 10.1016/S0304-3940(01)02071-7 · DOI
  36. Salo, 2016, Seipin regulates ER-lipid droplet contacts and cargo delivery, EMBO J., 35, 2699, 10.15252/embj.201695170 · DOI
  37. Seemann, 2000, The role of the tethering proteins p115 and GM130 in transport through the Golgi apparatus in vivo, Mol. Biol. Cell, 11, 635, 10.1091/mbc.11.2.635 · DOI
  38. Simón, 2012, Proteostasis of tau. Tau overexpression results in its secretion via membrane vesicles, FEBS Lett., 586, 47, 10.1016/j.febslet.2011.11.022 · DOI
  39. Steringer, 2018, A direct gateway into the extracellular space: Unconventional secretion of FGF2 through self-sustained plasma membrane pores, Semin. Cell Dev. Biol., 83, 3, 10.1016/j.semcdb.2018.02.010 · DOI
  40. Sun, 2009, Interaction of tea catechin (-)-epigallocatechin gallate with lipid bilayers, Biophys. J., 96, 1026, 10.1016/j.bpj.2008.11.007 · DOI
  41. Venkatachalam, 2003, Human 3′-phosphoadenosine 5′-phosphosulfate (PAPS) synthase: biochemistry, molecular biology and genetic deficiency, IUBMB Life, 55, 1, 10.1080/1521654031000072148 · DOI
  42. Wallbrecher, 2017, Membrane permeation of arginine-rich cell-penetrating peptides independent of transmembrane potential as a function of lipid composition and membrane fluidity, J. Control. Release, 256, 68, 10.1016/j.jconrel.2017.04.013 · DOI
  43. Wegmann, 2016, Formation, release, and internalization of stable tau oligomers in cells, J. Neurochem., 139, 1163, 10.1111/jnc.13866 · DOI
  44. Wilson, 1984, The structure of an antigenic determinant in a protein, Cell, 37, 767, 10.1016/0092-8674(84)90412-4 · DOI
  45. Wobst, 2015, The green tea polyphenol (-)-epigallocatechin gallate prevents the aggregation of tau protein into toxic oligomers at substoichiometric ratios, FEBS Lett., 589, 77, 10.1016/j.febslet.2014.11.026 · DOI
  46. Yan, 2016, FRMD4A-cytohesin signaling modulates the cellular release of tau, J. Cell Sci., 129, 2003, 10.1242/jcs.180745 · DOI
  47. Yurko-Mauro, 2010, Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline, Alzheimers Dement., 6, 456, 10.1016/j.jalz.2010.01.013 · DOI
  48. Zhang, 2016, Intakes of fish and polyunsaturated fatty acids and mild-to-severe cognitive impairment risks: a dose-response meta-analysis of 21 cohort studies, Am. J. Clin. Nutr., 103, 330, 10.3945/ajcn.115.124081 · DOI · Paper page

Cited by

Sorted by citations

Metadata

Authors
Merezhko, M., Brunello, C. A., Yan, X., Vihinen, H., Jokitalo, E., Uronen, R.-L., & Huttunen, H. J.
Venue
Cell Reports
Publisher
Elsevier BV
Published
2018-11
Volume
25
Issue
8
Pages
2027-2035.e4
ISSN
2211-1247
DOI
10.1016/j.celrep.2018.10.078
Cited by
166
References
8
Language
en
Licence
Funders
  • Université de Montréal
  • Academy of Finland (296409)
  • Suomen Kulttuurirahasto

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review